Novartis Trades at a Discount as It Rewires Drug Discovery Around Outside Science

Novartis licenses Abogen's ABO2203 in a deal worth up to $7.2B in milestones, adds 160M reactions from CAS, while Goldman keeps a Sell rating.

Novartis is rebuilding its early-stage research engine at a moment when the market is in no mood to pay for promise. The Swiss drugmaker's shares changed hands at 125.16 euros on Friday after a 0.4 percent slip, leaving the stock about 13 percent below its 52-week peak of 144.30 euros — a valuation gap that has widened since a pair of late-stage clinical failures in September wiped close to 30 billion US dollars off its market capitalization.

Rather than retreat, management has doubled down on external science. The most consequential move is a licensing pact with Chinese biotech Abogen Biosciences, which hands Novartis worldwide exclusive rights to the experimental candidate ABO2203 plus options on additional RNA programs. The structure is deliberately back-loaded: Abogen collects 575 million US dollars upfront, with as much as 7.2 billion US dollars in milestone payments contingent on hitting defined development, regulatory and commercial targets. Tiered royalties on future product sales round out the terms, and closing remains subject to customary conditions.

An mRNA Candidate Aimed at Autoimmune Disease

ABO2203 is an in-vivo T-cell engager (CD19xCD3) that uses mRNA technology to target disease-relevant B cells in autoimmune conditions such as lupus and rheumatoid arthritis. It sits at the center of a broader pivot toward Asia's fast-maturing research base — a shift with hard numbers behind it. Work by consultancy McKinsey shows Chinese companies now push clinic-ready molecules through development 50 to 70 percent faster than the international average, while recruiting patients for late-stage trials two to five times more quickly. Roughly a third of all global development candidates now originate in Chinese labs, and more than half of worldwide licensing and collaboration transaction volume involves assets from the region. For a company nursing holes in its mid-term pipeline, that access offers a way to plug gaps with assets that are already far along.

A 160-Million-Reaction Data Engine

The Abogen deal is only one strand of the strategy. On September 30, Novartis Biomedical Research struck a collaboration with CAS to widen its access to reaction data for laboratory analysis and AI-assisted development. Under the arrangement, CAS supplies the research arm with more than 160 million curated chemical reactions. The goal is to compress development timelines and lift hit rates in molecule hunting — a capability that matters more as computational prediction takes over work that once consumed expensive bench time. Such tie-ups are spreading quickly across pharma, where every avoided dead end in the lab translates into saved capital.

Goldman Stays on the Sidelines

Not everyone is buying the longer-term story just yet. On Thursday, Goldman Sachs's James Quigley lifted his price target on Novartis to 113 francs from 110 while keeping a "Sell" rating, with his third-quarter 2026 estimates landing broadly in line with consensus. The caution captures the central tension: heavy upfront spending on platform technologies and partnerships has yet to convert into near-term operating earnings.

The next hard test arrives on October 27, 2026, when Novartis publishes detailed third-quarter 2026 results. Until then, investors are likely to focus on a single question — how quickly the newly signed research collaborations can translate into measurable progress across the clinical pipeline.